Targeting phosphoinositide 3-kinase δ for the treatment of respiratory diseases
- PMID: 23551101
- DOI: 10.1111/nyas.12039
Targeting phosphoinositide 3-kinase δ for the treatment of respiratory diseases
Abstract
Asthma and chronic obstructive pulmonary disease (COPD) are characterized in their pathogenesis by chronic inflammation in the airways. Phosphoinositide 3-kinase δ (PI3Kδ), a lipid kinase expressed predominantly in leukocytes, is thought to hold much promise as a therapeutic target for such inflammatory conditions. Of particular interest for the treatment of severe respiratory disease is the observation that inhibition of PI3Kδ may restore steroid effectiveness under conditions of oxidative stress. PI3Kδ inhibition may also prevent recruitment of inflammatory cells, including T lymphocytes and neutrophils, as well as the release of proinflammatory mediators, such as cytokines, chemokines, reactive oxygen species, and proteolytic enzymes. In addition, targeting the PI3Kδ pathway could reduce the incidence of pathogen-induced exacerbations by improving macrophage-mediated bacterial clearance. In this review, we discuss the potential and highlight the unknowns of targeting PI3Kδ for the treatment of respiratory disease, focusing on recent developments in the role of the PI3Kδ pathway in inflammatory cell types believed to be critical to the pathogenesis of COPD.
© 2013 New York Academy of Sciences.
Similar articles
-
Targeting phosphoinositide 3-kinase δ for allergic asthma.Biochem Soc Trans. 2012 Feb;40(1):240-5. doi: 10.1042/BST20110665. Biochem Soc Trans. 2012. PMID: 22260698 Review.
-
The effect of phosphatidylinositol-3 kinase inhibition on matrix metalloproteinase-9 and reactive oxygen species release from chronic obstructive pulmonary disease neutrophils.Int Immunopharmacol. 2016 Jun;35:155-162. doi: 10.1016/j.intimp.2016.03.027. Epub 2016 Apr 16. Int Immunopharmacol. 2016. PMID: 27049289
-
Phosphoinositide 3-kinase delta (PI3Kδ) in leukocyte signaling and function.Cell Signal. 2011 Apr;23(4):603-8. doi: 10.1016/j.cellsig.2010.10.002. Epub 2010 Oct 16. Cell Signal. 2011. PMID: 20940048 Review.
-
A role for phosphoinositol 3-kinase delta in the impairment of glucocorticoid responsiveness in patients with chronic obstructive pulmonary disease.J Allergy Clin Immunol. 2010 May;125(5):1146-53. doi: 10.1016/j.jaci.2010.02.003. Epub 2010 Apr 9. J Allergy Clin Immunol. 2010. PMID: 20381852
-
Phosphoinositide 3-kinase δ (PI3Kδ) in respiratory disease.Biochem Soc Trans. 2018 Apr 17;46(2):361-369. doi: 10.1042/BST20170467. Epub 2018 Mar 9. Biochem Soc Trans. 2018. PMID: 29523773 Review.
Cited by
-
Developing PI3K Inhibitors for Respiratory Diseases.Curr Top Microbiol Immunol. 2022;436:437-466. doi: 10.1007/978-3-031-06566-8_19. Curr Top Microbiol Immunol. 2022. PMID: 36243856
-
PI3Kδ inhibition prevents IL33, ILC2s and inflammatory eosinophils in persistent airway inflammation.BMC Immunol. 2021 Dec 17;22(1):78. doi: 10.1186/s12865-021-00461-5. BMC Immunol. 2021. PMID: 34920698 Free PMC article.
-
Physiologically Based Pharmacokinetic Modelling of Inhaled Nemiralisib: Mechanistic Components for Pulmonary Absorption, Systemic Distribution, and Oral Absorption.Clin Pharmacokinet. 2022 Feb;61(2):281-293. doi: 10.1007/s40262-021-01066-2. Epub 2021 Aug 30. Clin Pharmacokinet. 2022. PMID: 34458976 Free PMC article.
-
A Review of Repurposed Cancer Drugs in Clinical Trials for Potential Treatment of COVID-19.Pharmaceutics. 2021 May 30;13(6):815. doi: 10.3390/pharmaceutics13060815. Pharmaceutics. 2021. PMID: 34070725 Free PMC article. Review.
-
PI3Kδ Inhibition as a Potential Therapeutic Target in COVID-19.Front Immunol. 2020 Aug 21;11:2094. doi: 10.3389/fimmu.2020.02094. eCollection 2020. Front Immunol. 2020. PMID: 32973818 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
